Drug intelligence / Profile preview

N501-CYMMAF

Development stage: Preclinical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

N501-CYMMAF is a novel near-infrared (NIR) ratiometric fluorescent antibody-drug conjugate (ADC) designed for the theranostic management of metastatic ovarian cancer. It consists of the n501 antibody, which provides high-affinity targeting to ovarian cancer cells, conjugated to the cytotoxic payload monomethyl auristatin F (MMAF) and a cyanine-based ratiometric fluorescent probe via a stimuli-cleavable linker. This "smart" theranostic agent enables targeted delivery of MMAF to inhibit tubulin polymerization while simultaneously allowing for real-time, in situ monitoring of treatment response through ratiometric fluorescence imaging. This dual functionality facilitates the identification of treatment-evading metastatic cell populations and provides insights into tumor recurrence pathways, helping to determine treatment endpoints.

Other names: cyanine-decorated Monomethylauristatin F

Targets

TUBB (Tubulin (alpha and beta subunits))TPBG (Trophoblast glycoprotein)

Beyond the preview

Go deeper on N501-CYMMAF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N501-CYMMAF.

Explore the full profile